Signal category
Track how regulatory decisions alter competitive positioning, launch timelines, and investor expectations across therapeutic areas.
FDA approvals, label changes, advisory committee outcomes, and global regulatory shifts that reshape asset and portfolio strategy.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.
Lupin
Asset
FDA
Indication
Metabolic Disorders / Urea Cycle Disorders
Status
Approved
Signal Score
8.4
The FDA has approved the application ANDA207694 for Glycerol Phenylbutyrate submitted by Lupin.
Unichem
Indication
Neurology / Pain Management
Status
Approved
Signal Score
8.4
The FDA has approved the ANDA219593 application for Pregabalin submitted by Unichem.
Apotex
Indication
Diabetes / DPP-4 Inhibitor and Biguanide
Status
Approved
Signal Score
8.4
The FDA has approved the combination of Sitagliptin and Metformin Hydrochloride under application ANDA202426 by Apotex.
Company
Novartis
Asset
Pluvicto
Indication
Oncology / Radiopharmaceutical
Status
Approved
Signal Score
8.4
The FDA has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for use in combination with androgen receptor pathway inhibitors in adults with PSMA-positive metastatic prostate cancer.
Asset
Resmed
Indication
Respiratory / Ventilation
Status
Under Review
Signal Score
8.4
Resmed has issued a correction for certain Astral ventilators due to a failure of an electrical component that may lead to therapy interruption or failure.
Company
Gilead
Asset
VEKLURY (Remdesivir)
Indication
Infectious Disease / Antiviral
Status
Approved
Signal Score
8.4
The FDA has approved a supplemental application for VEKLURY (remdesivir) submitted by Gilead Sciences.
QLONILIK
Indication
Neurology / Antihypertensive
Status
Approved
Signal Score
8.4
The FDA has approved QLONILIK, containing Clonidine Hydrochloride, under NDA221094.
Asset
FDA
Indication
Anesthesia / Neuromuscular Blockade
Status
Approved
Signal Score
8.4
The FDA has granted approval for Sugammadex Sodium under application ANDA218814 submitted by SteriScience.
Teva
Asset
Sugammadex
Indication
Anesthesia / Neuromuscular Blockade
Status
Approved
Signal Score
8.4
Teva Pharmaceuticals has received an Abbreviated New Drug Application (ANDA) approval status for Sugammadex Sodium.
Asset
FDA
Indication
Anesthesia / Neuromuscular Blockade
Status
Approved
Signal Score
8.4
The FDA has granted approval for the ANDA219448 application for Sugammadex Sodium submitted by Fresenius Kabi.
Reddy's has received FDA approval for Sugammadex Sodium under ANDA214236.
Sandoz
Asset
Sugammadex Sodium
Indication
Anesthesia / Neuromuscular Blockade
Status
Approved
Signal Score
8.4
Sandoz has received an Abbreviated New Drug Application (ANDA) approval for Sugammadex Sodium.
Gland Pharma
Asset
FDA
Indication
Anesthesia / Reversal Agent
Status
Approved
Signal Score
8.4
The FDA has approved Sugammadex Sodium under application ANDA214364 submitted by Gland Pharma.
FDA
Indication
Anesthesia / Neuromuscular Blockade
Status
Approved
Signal Score
8.4
The FDA has granted approval for Sugammadex Sodium under ANDA214368, submitted by MSN.
Company
AstraZeneca
Asset
Datroway
Indication
Oncology / Breast Cancer
Status
Approved
Signal Score
8.4
Datroway has been approved in the EU as the only TROP2-directed therapy demonstrating overall survival benefit for first-line treatment in metastatic TNBC patients not eligible for immunotherapy.
Asset
Cipla
Indication
Oncology / Small Molecule
Status
Approved
Signal Score
8.4
Cipla's application ANDA210435 for Lenalidomide has received an abbreviated approval status from the FDA.
ACADIA PHARMS INC.
Asset
NUPLAZID
Indication
Parkinson's Disease market
Status
Approved
Signal Score
8.4
The FDA has granted priority review status for the supplemental NDA for NUPLAZID, an indication for pimavanserin tartrate.
Asset
Aficamten
Indication
Cardiology / Heart Failure
Status
Approved
Signal Score
8.4
Aficamten has received approval from the MHRA and a recommendation from NICE for use in patients with a serious heart condition.
Asset
FDA
Indication
Oncology / Sarcoma
Status
Approved
Signal Score
8.4
The FDA has granted accelerated approval for afamitresgene autoleucel, TCR therapy targeting MAGE-A4 in synovial sarcoma.
Company
Pfizer
Asset
European
Indication
Infectious Disease / COVID-19 Vaccine
Status
Approved
Signal Score
8.4
The European Commission has granted marketing authorization for the Pfizer-BioNTech XFG-adapted COVID-19 vaccine for individuals 6 months and older.
Asset
Lenalidomide
Indication
Hematology / Multiple Myeloma
Status
Approved
Signal Score
8.4
The FDA has approved the ANDA217554 submission for Lenalidomide by Deva Holding AS.
ACADIA Pharmaceuticals
Asset
NUPLAZID
Indication
Parkinson's Disease market
Status
Approved
Signal Score
8.4
The FDA has granted priority review status for the supplemental application of NUPLAZID (pimavanserin tartrate) submitted by ACADIA Pharmaceuticals.
Torrent Pharmaceuticals
Asset
FDA
Indication
Oncology / Small Molecule
Status
Approved
Signal Score
8.4
The FDA has accepted the ANDA submission for Lenalidomide from Torrent Pharmaceuticals.
Mylan
Asset
Pomalidomide
Indication
multiple myeloma therapies
Status
Approved
Signal Score
8.4
The FDA has granted approval for a supplemental application for Pomalidomide submitted by Mylan.
Ezplaz
Indication
Hematology / Plasma Products
Status
Approved
Signal Score
8.4
The FDA has licensed Ezplaz Freeze Dried Plasma, the first of its kind in the U.S., for transfusion in adults.
Outlook Therapeutics
Asset
Bevacizumab
Indication
Oncology / Monoclonal Antibody
Status
Approved
Signal Score
8.4
The FDA has approved LYTENAVA (BLA761320), a new formulation of Bevacizumab by Outlook Therapeutics.
Otsuka Pharmaceutical
Asset
Simtriyo
Indication
Neurology / ADHD
Status
Approved
Signal Score
8.4
The FDA has granted priority review status for Otsuka Pharmaceutical's NDA for Simtriyo, containing centanafadine.
Alembic Pharmaceuticals
Asset
FDA
Indication
Neurology / Multiple Sclerosis
Status
Approved
Signal Score
8.4
The FDA has granted approval for the ANDA207974 application for Fingolimod Hydrochloride submitted by Alembic.
NATCO
Indication
Oncology / Antineoplastic
Status
Approved
Signal Score
8.4
The FDA has granted approval for the thalidomide application ANDA213267 submitted by NATCO.
Otsuka Pharmaceutical
Asset
Simtriyo
Indication
Neurology / ADHD
Status
Approved
Signal Score
8.4
The FDA has granted priority review status for Otsuka's NDA for Simtriyo, an ADHD treatment containing centanafadine.
OUTLOOK THERAPEUTICS, INC.
Asset
LYTENAVA
Indication
Oncology / Monoclonal Antibody
Status
Approved
Signal Score
8.4
The FDA has approved LYTENAVA, a new formulation of bevacizumab, under application BLA761320.
Zydus Pharmaceuticals
Asset
Edaravone
Indication
Neurology / ALS
Status
Approved
Signal Score
8.4
The FDA has granted approval for Zydus Pharmaceuticals' Abbreviated New Drug Application for Edaravone.
JIDEYTRO
Indication
Oncology / Small Molecule
Status
Approved
Signal Score
8.4
The FDA has approved JIDEYTRO (ZIDESAMTINIB) under NDA220185 submitted by Nuvalent Inc.
Asset
Karyopharm
Indication
Oncology / Small Molecule
Status
Approved
Signal Score
8.4
The FDA has granted approval status (AP) for Karyopharm's NDA212306 for XPOVIO (Selinexor).
Roche
Asset
Susvimo
Indication
Ophthalmology / Neovascular Age-Related Macular Degeneration
Status
Approved
Signal Score
9.6
The CHMP has recommended the approval of Susvimo, a continuous delivery treatment for nAMD, based on clinical trial data.
Company
Roche
Asset
FDA
Indication
Nephrology / Autoimmune Disease
Status
Approved
Signal Score
9.6
The FDA has granted Priority Review for Gazyva/Gazyvaro based on phase III MAJESTY results showing superior remission rates in primary membranous nephropathy.
Company
Pfizer
Asset
Astellas
Indication
Oncology / Bladder Cancer
Status
Approved
Signal Score
9.6
The FDA has approved PADCEV in combination with Keytruda as a neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer, regardless of cisplatin eligibility.
Veklury
Indication
Infectious Disease / Antiviral
Status
Approved
Signal Score
9.6
The FDA has approved Veklury (remdesivir) as the first treatment for COVID-19 in hospitalized patients.
9.6
The Phase III Krascendo 1 trial demonstrated that divarasib significantly improves progression-free and overall survival compared to existing KRAS G12C inhibitors.
Company
Immunocore
Asset
Oncology
Indication
uveal melanoma
Status
Approved
Signal Score
9.6
Tebentafusp (IMCgp100) significantly improved overall survival in HLA-A*02:01-positive advanced uveal melanoma, establishing it as a first-line treatment.
Merck
Asset
ENFLONSIA
Indication
Infectious Disease
Status
Approved
Signal Score
9.6
The European Commission has approved ENFLONSIA (clesrovimab) as the first RSV preventive option for infants in the EU.
Company
Roche
Asset
Gazyva
Indication
Immunology / Systemic Lupus Erythematosus
Status
Approved
Signal Score
9.6
The FDA has accepted Roche's sBLA for Gazyva/Gazyvaro, based on phase III ALLEGORY data showing significant efficacy in SLE.
Company
Roche
Asset
Neurology
Indication
Alzheimer's Disease
Status
Approved
Signal Score
9.6
Roche has received CE Mark approval for Elecsys® pTau217, the first blood test for Alzheimer's disease pathology, enabling faster diagnosis.
AstraZeneca
Asset
Truqap
Indication
PTEN-deficient metastatic hormone-sensitive prostate cancer
Status
Approved
Signal Score
9.6
The FDA ODAC has recommended Truqap in combination with abiraterone and ADT for PTEN-deficient metastatic hormone-sensitive prostate cancer.
Company
AstraZeneca
Asset
Datroway
Indication
triple-negative breast cancer
Status
Approved
Signal Score
9.6
Datroway is approved in the US as the first TROP2-directed antibody drug conjugate for 1st-line treatment of metastatic triple-negative breast cancer.
Company
Roche
Asset
Oncology
Indication
early-stage ER-positive breast cancer
Status
Approved
Signal Score
9.6
The FDA has accepted Roche's NDA for giredestrant, an oral SERD, under priority review based on phase III data showing a 30% reduction in invasive disease recurrence or death compared to standard therapy.
Company
Roche
Asset
Oncology
Indication
early-stage ER-positive breast cancer
Status
Approved
Signal Score
9.6
The FDA has accepted Roche's NDA for giredestrant, showing a 30% reduction in invasive disease recurrence compared to standard therapy.
Company
Roche
Asset
Tecentriq
Indication
stage III colon cancer market
Status
Approved
Signal Score
9.6
The FDA has accepted Roche's sBLA for Tecentriq plus chemotherapy in stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.